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Topotecan (10-hydroxy-9-dimethyl-amino-methyl-camptothecin)
is a new topoisomerase-I (TOP-I) targeting agent with significant
clinical efficacy against a variety of solid tumours (Slichenmeyer
et al, 1993; Rowinsky et al, 1997). Like other TOP-I interactive
agents topotecan interacts with the breakage-rejoining reaction
between DNA and TOP-I, generating intermediate forms of drug-
stabilized covalent DNA–TOP-I complexes, referred to as cleav-
able complexes (Hsiang et al, 1988; Liu, 1989; Chen et al, 1994;
Pommier et al, 1996). The cellular accumulation of such
complexes may lead to cell death due to replication arrest and
replication fork disassembly as well as chromosomal fragmenta-
tion (Covey et al, 1989; Ryan et al, 1991, 1994; Tsao et al, 1993).
Like other camptothecin (CPT) analogues, topotecan establishes
an equilibrium between the pharmacologically active closed
lactone ring and the inactive open ring hydroxy acid form by
reversible pH-dependent cellular hydrolysis (Grochow et al,
1992).
Acquired resistance to TOP-I interactive drugs has been related
to down-regulation of TOP-I gene and protein expression (Eng
et al, 1990; Kanzawa et al, 1990; Sugimoto et al, 1990; Kapoor et
al, 1995; Sorensen et al, 1995) as well as alterations in TOP-I
structure and function (e.g. point mutations, deletions and
rearrangements of the TOP-I gene) (Andoh et al, 1987; Tan et al,
1989; Benedetti et al, 1993; Gromova et al, 1993). Current data
suggest that positively charged CPT derivatives (e.g. topotecan)
may be also transported by the MDR1 gene product P170-glyco-
protein (P-gp), a Mr 170 000 energy-dependent transmembrane
glycoprotein efflux pump (Hendricks et al, 1992; Mattern et al,
1993; Maliepaard et al, 1996). Although altered cellular drug
accumulation has been related to topotecan resistance, so far only
few data are available on cellular pharmacokinetics of the pharma-
cologically active lactone form of topotecan and reversing agents
of topotecan resistance in P-gp-expressing multidrug-resistant
(MDR) cells (Hendricks et al, 1992).
The dihydropyridine analogue PAK-200S (2-[benzyl(phenyl)-
amino]ethyl-1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-
oxo-1,3,2-dioxaphosphorinan-2-yl)-1-(2-morpholinoethyl)-4-
(3-nitrophenyl)-3-pyridinecarboxylate) is an effective chemosen-
sitizing modulator of membrane protein-associated drug resistance
(P-gp and multidrug resistance protein [MRP]; U Vanhoefer et al,
unpublished data) with a broad spectrum of activity in vitro and in
vivo (Niwa et al, 1992). It has been shown that non-cytotoxic
concentrations of PAK-200S inhibited [3H]azidopine photo-
labelling of P-gp, associated with reversal of drug resistance in
MDR KB-C2 and xenografted COK-36LN cells. An important
feature in terms of clinical application of the dihydropyridine
analogue PAK-200S is that this agent has the advantage over other
calcium antagonists to exert effective P-gp modulatory properties
with no significant calcium channel-blocking activity or other in
vivo toxicity.
The present study describes the effects of the new dihydropyri-
dine analogue PAK-200S on the cellular determinants of resistance
Reversal of MDR1-associated resistance to topotecan
by PAK-200S, a new dihydropyridine analogue, in human
cancer cell lines
U Vanhoefer1, MR Müller1, RA Hilger1, B Lindtner1, U Klaassen1, N Schleucher1, YM Rustum2, S Seeber1
and A Harstrick1
1Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Essen Medical School, 45122 Essen, Germany; 2Department
of Pharmacology and Therapeutics, Grace Cancer Drug Center, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo 14263, New York, USA
Summary Recent data suggest that expression of the membrane P170-glycoprotein (P-gp) may confer resistance to the topoisomerase-
I-interactive agent topotecan. The present study describes the cellular effects of a new dihydropyridine analogue, PAK-200S, on
P-gp-mediated resistance to topotecan in human breast and ovarian tumour cells. PAK-200S at a non-cytotoxic concentration of 2.0 mM
completely reversed resistance to topotecan in P-gp-expressing MCF-7/adr (breast) and A2780/Dx5 (ovarian) tumour cells, respectively, with
no effects on parental cells. Cellular pharmacokinetic studies by reversed-phase high-performance liquid chromatography analysis showed
significantly lower cellular drug concentrations of the pharmacologically active closed-ring lactone of topotecan in multidrug-resistant cells
than in parental cells. PAK-200S was effective in restoring the cellular lactone concentrations of topotecan in resistant MCF-7/adr cells to
levels comparable to those obtained in parental cells. Furthermore, exposure of MCF-7/adr cells to topotecan in the presence of PAK-200S
significantly increased the induction of protein-linked DNA breaks. PAK-200S did not alter nuclear topoisomerase I-mediated ex vivo pBR322
DNA plasmid unwinding activity and topoisomerase-I protein expression. These results suggest that reversal of P-gp-mediated resistance to
topotecan by PAK-200S was related to the restoration of cellular drug concentrations of the active lactone form of topotecan rather than a
direct effect on topoisomerase-I function. © 1999 Cancer Research Campaign
Keywords: topotecan; PAK-200S; multidrug resistance; breast cancer; ovarian cancer
1304
British Journal of Cancer (1999) 81(8), 1304–1310
© 1999 Cancer Research Campaign
Article no. bjoc.1999.0845
Received 26 February 1999
Revised 11 June 1999
Accepted 16 June 1999
Correspondence to: U VanhoeferReversal of MDR1-associated topotecan resistance 1305
British Journal of Cancer (1999) 81(8), 1304–1310 © 1999 Cancer Research Campaign
to topotecan in MDR human ovarian A2780/Dx5 and breast
MCF-7/adr tumour cells that express the P-gp phenotype.
MATERIALS AND METHODS
Chemicals
Topotecan was obtained from SmithKline Beecham (King of
Prussia, Philadelphia, PA, USA) and dissolved in dimethyl
sulphoxide (DMSO) at a concentration of 10 mM (stock solution).
PAK-200S was supplied by Nissan Chemical Ind. Co. (Chiba,
Japan) and dissolved in DMSO (stock solution 10 mM). The
highest concentration of DMSO used in all assays was found to be
non-cytotoxic and without effect on the biochemical assays.
Cell lines
The characteristics of the human ovarian cancer cell line
A2780/wt (parental), the MDR subline A2780/Dx5 (P-gp-positive,
MRP-negative), the human breast cancer cell line MCF-7/wt
(parental) and the MDR subline MCF-7/adr (P-gp-positive, MRP-
negative) have been reported previously (Fairchild et al, 1987;
Minderman et al, 1996). Parental and resistant A2780 and MCF-7
cells were grown as monolayer in RPMI-1640 medium supple-
mented with 10% heat-inactivated fetal calf serum (FCS), and
2m ML -glutamine. Cell cultures were kept in a humidified atmos-
phere of 5% carbon dioxide in air at 37°C. P-gp expression in
A2780/Dx5 and MCF-7/adr cells was confirmed by flow cyto-
metric analysis using monoclonal antibody (mAb) UIC2 (Müller
et al, 1994). Representative histograms of single parameter green
fluorescence plots showed a homogeneous population of MCF-
7/adr cells staining for P-gp, while two subpopulations with
different P-gp expression were found in the A2780/Dx5 cell line
(data not shown) as already reported earlier (Minderman et al,
1996). Thus, MCF-7/wt and MCF-7/adr cells were used only for
further biochemical analysis.
In vitro cytotoxicity
Drug sensitivity was assessed by the sulphorhodamine B (SRB)-
assay (Skehan et al, 1990). Exponentially growing human ovarian
carcinoma A2780/wt and MDR A2780/Dx5 cells were seeded at a
density of 1000 cells well–1 in 96-well microtitre plates (Falcon,
Becton-Dickinson Labware, Plymouth, UK) and allowed to attach
overnight. Human breast cancer cells MCF-7/wt and MDR MCF-
7/adr cells were seeded at a density of 800 cells well–1. After 24 h
cells were exposed for 24 h either to topotecan or to doxorubicin,
respectively, washed twice with phosphate-buffered saline (PBS)
and reincubated in drug-free medium. At four cell doubling times
after beginning of drug treatment, cells were fixed with trichloric
acetic acid, washed and stained with sulphorhodamine B as origi-
nally described. For modulation studies the cells were exposed for
24 h to the drug alone or in combination with a non-cytotoxic
concentration (2.0 mM) of PAK-200S, washed twice with PBS and
reincubated in drug-free medium with or without
the modulator. The absorbance was measured at 570 nm using a
96-well plate reader (340 EL BIO Kinetics Reader, Bio-Tek
Instruments Inc., Winooski, VT, USA). The drug concentrations
which inhibited cell growth by 50% (IC50) were determined from
semilogarithmic dose–response plots.
RP-HPLC-analysis of topotecan concentrations
Exponentially growing cells were trypsinized, washed twice with
PBS and 2 ´ 106 cells per sample were resuspended in RPMI-1640
medium. Then, cells were exposed to drug-free medium or to
medium containing 2.0 mM PAK-200S for 30 min at 37°C. For
the measurements of cellular topotecan concentrations, 1.0 mM
topotecan was added for the indicated time. For reversed-phase
high-performance liquid chromatography (RP-HPLC) analysis
cells were centrifuged at 11 000 g at 4°C, washed twice in ice-cold
PBS buffer and resuspended in 500 ml of 0.1 M sodium citrate
solution, and the extraction procedure was performed as described
earlier (Beijnen et al, 1990). In brief, cells were lysed and de-
proteinized with 3 ml ice-cold methanol–acetonitrile (50:50, v/v),
covered with nitrogen and frozen at –20°C for 12 h. After centrifu-
gation at 1000 g for 15 min, supernatants were evaporated in a
Speed Vac Plus Concentrator (Savant Instruments Inc., Farming-
dale, NY, USA), resuspended in 200 ml of the mobile phase
(methanol–phosphate buffer [60:40, v/v] adjusted to pH 5.9),
covered with nitrogen and stored at –20°C for a further 2 h. The
samples were centrifuged (21 900 g at 4°C for 5 min), and 50 ml of
each sample were applied to HPLC. HPLC was performed with
reversed-phase columns (4.6 ´ 250 mm) at 20°C packed with
Nucleosil (C18) 5-mm particles (Machery and Nagel, Düren,
Germany); sample injections were performed using a Waters 717
Plus Autosampler (Waters Inc., Eschborn, Germany). Absorbance
of the column effluent was monitored using a fluorescence
detector (Waters 470 Scanning Fluorescence Detector). Excitation
was set to 370 nm and emission was adjusted to 525 nm. The peak
areas were calculated using a Waters Millennium Chromatography
Manager. Linearity was given to r2 = 0.999 in the range of
5.0  mM–1.0 mM TPT, the limit of detection was 20 pM, the limit of
quantitation was 50 pM (data not shown).
TOP-I and TOP-II protein expression
Fifty micrograms of nuclear proteins were dissolved on a 7.5%
sodium dodecyl sulphate (SDS) polyacrylamide gel and electro-
blotted to nitrocellulose (Bio-Rad, Hercules, CA, USA). For TOP-
I immunoblotting, membranes were blocked with 5% (w/v) dried
non-fat milk in PBS. TOP-I-specific binding of the human mAb
against TOP-I (TopoGen Inc., Columbus, OH, USA) was visual-
ized with the enhanced chemiluminescence (ECL) detection
(Amersham Co., Arlington Heights, IL) using a protein A–horse-
radish peroxidase complex (Amersham Co.). TOP-II-specific
binding of a rabbit polyclonal Ab (TopoGen Inc.) was visualized
as mentioned above using a horseradish peroxidase complex.
TOP-I unwinding activity of pBR322 plasmid DNA
Nuclear extracts were prepared according to the method of Danks
et al (1988). In brief, 108 cells were permeabilized in 5 mM
potassium dihydrogen phosphate buffer pH 7.0 containing 2 mM
magnesium chloride (MgCl2), 4 mM dithiothreitol (DDT), 0.1 mM
ethylenediaminetetraacetic acid (EDTA), and 1 mM phenyl-
methylsulphonyl fluoride (PMSF) (buffer A). Then, cells were
centrifuged at 400 g for 5 min, and resuspended in buffer A
containing 0.25 M sucrose, overlayed with buffer A containing
0.3 M sucrose and centrifuged at 2000 g for 20 min. The pellet was
resuspended in 5 mM potassium dihydrogen phosphate buffer pH
7.0 containing 4 mM DTT, 1 mM EDTA and 1 mM PMSF. Nuclear1306 U Vanhoefer et al
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proteins were eluted as 0.35 and 1.0 M salt extracts as originally
described, washed and stored in aliquots at –80°C. To evaluate the
effect of PAK-200S on the topotecan-mediated inhibition of ATP-
independent unwinding of supercoiled pBR322 plasmid DNA ex
vivo, a reaction mixture containing 0.3 mg ml–1 pBR322 plasmid
DNA and different dilutions of nuclear extract protein were incu-
bated at exactly 37°C for 30 min with drug-free medium or with
50 mM topotecan ± 2.0 mM PAK-200S. The reaction products were
separated on a 1.0% (w/v) agarose gel (4.6 V cm–1) and stained
with 0.5 mg ml–1 ethidium bromide. Topotecan, DMSO and
PAK-200S at the concentrations used had no effect on the pBR322
plasmid DNA (data not shown).
Quantitation of protein-linked DNA breaks
The DNA of mid-logarithmic phase MCF-7/adr cells was labelled
for 24 h with 0.1 mCi ml–1 [14C]dThy (DuPont, Boston, MA, USA;
specific activity 62.8 mCi mmol–1). Cells were harvested, washed
and reincubated for 30 min at 37°C in [14C]dThy-free medium
containing 1.0–100 mM TPT with or without 2.0 mM PAK-200S.
After drug exposure cells were washed in pre-warmed PBS (37°C)
and the potassium chloride–SDS co-precipitation assay was
immediately performed using 1 ml lysis buffer (1.25% SDS, 5 mM
EDTA, 0.4 mg ml–1 sheared salmon sperm DNA, adjusted to pH
8.0) per 106 cells as described earlier (Trask et al, 1984; Vanhoefer
et al, 1997). The results were calculated as percentage of pre-
cipitable [14C]dThy-labelled DNA of drug-treated cells of total
[14C]dThy-DNA.
Statistical analysis
The differences between the mean values were analysed for
significance using the unpaired two-tailed Student’s t-test for




The cytotoxicity of a 24-h drug exposure to doxorubicin (Figure
1A) and topotecan (Figure 1B) was investigated in parental and
resistant MCF-7 and A2780 cells. MCF-7/adr and A2780/Dx5
cells showed 88-fold and 189-fold resistance to doxorubicin,
whereas cross-resistance to topotecan was 5.6-fold and 23.6-fold,
respectively. Cellular exposure to a non-cytotoxic concentration of
PAK-200S (2 mM) partially reversed resistance to doxorubicin, but
almost completely restored sensitivity to topotecan in both MDR
cell lines (remaining resistance to topotecan in MCF-7/adr and
A2780/Dx5 cells was 1.8-fold (P > 0.05) and 1.6-fold (P > 0.05),
respectively) with no effect on parental MCF-7/wt and A2780/wt
cells.
Pharmacokinetics of cellular topotecan concentrations
The cellular topotecan concentrations in parental MCF-7/wt and
P-gp-expressing MCF-7/adr cells were analysed by RP-HPLC and
the results are shown in Figure 2. Cellular topotecan lactone
concentrations in MCF-7/wt and MCF-7/adr cells were accumu-
lated with steady-state levels at approximately 20 min. Resistant
MCF-7/adr cells showed about 2.5-fold lower cellular lactone
concentrations than parental MCF-7/wt cells with peak intra-
cellular concentrations of 19.55 ± 3.19 pmol topotecan lactone
10–6 cells and 48.87 ± 3.92 pmol topotecan lactone 10–6 cells,
respectively (P < 0.01). Exposure of MCF-7/adr cells to a non-
cytotoxic concentration of 2.0 mM PAK-200S completely restored
cellular lactone concentrations with 47.56 ± 2.98 pmol lactone
10–6 cells to the level observed for MCF-7/wt cells. PAK-200S had
no effect on the drug concentrations in parental MCF-7/wt lacking













































































































Figure 1 Modulation of cellular resistance to doxorubicin (Dox) and topotecan (TPT) by a non-cytotoxic concentration of the dihydropyridine analogue PAK-
200S in P-gp-expressing A2780/Dx5 and MCF-7/adr multidrug-resistant cells. Cytotoxicity was determined with the sulphorhodamine B (SRB) assay as
described in Materials and Methods; all experiments were performed at least in triplicateReversal of MDR1-associated topotecan resistance 1307
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parental A2780/wt and resistant A2780/Dx5 cells (data not
shown).
Immunoblot analysis of TOP-I and TOP-II expression
A representative TOP-I and TOP-II immunoblot of parental MCF-
7/wt and resistant MCF-7/adr cells is shown in Figure 3A. Two
bands were identified, the intact Mr 100 000 TOP-I protein band
and a Mr 68 000 TOP-I proteolytic fragment (D’Arpa et al, 1988).
No differences in TOP-I protein expression were found between
topotecan-sensitive and -resistant MCF-7/wt cells. However, using
a rabbit polyclonal antibody against TOP-II protein, MCF-7/adr
cells revealed a minimally lower expression of TOP-II. Exposure
of MCF-7/adr cells to 2 mM PAK-200S did not affect either TOP-I
or TOP-II expression (Figure 3B).
Induction of protein-linked DNA breaks
The maximum induction of protein-linked DNA breaks (PLDBs)
by topotecan without or with PAK-200S was investigated in MCF-
7/adr cells (Figure 4). After a 30-min exposure to increasing
concentrations of topotecan, the induction of PLDBs increased in a
dose-dependent manner (demonstrated as maximal induction of
PLDBs), followed by a plateau phase. Exposure of MCF-7/adr
cells to topotecan in the presence of a non-cytotoxic concentration
of 2.0 mM PAK-200S significantly increased the maximum induc-
tion of PLDBs (PLDBs for 50 mM topotecan without or with
2.0 mM PAK-200S were 10.5 ± 2.1% vs 16.9 ± 4.4% (P < 0.01),
respectively), demonstrating increased binding of topotecan to the
nuclear DNA–TOP-I complex. No effect of PAK-200S on the
maximum induction of PLDBs was found in parental MCF-7/wt
cells (data not shown).
TOP-I DNA unwinding activity
The effect of PAK-200S on the topotecan-mediated inhibition of
the unwinding activity of TOP-I was investigated ex vivo using
nuclear extracts of MCF-7/adr cells. The quantitation of ATP-
independent TOP-I DNA unwinding activity was accomplished
ex vivo by adding nuclear extracts to a reaction mixture containing
supercoiled pBR322-DNA as substrate and the results are shown
in Figure 5. Exposure of nuclear extracts to 50 mM of topotecan
significantly inhibited TOP-I unwinding activity at 160 ng of
nuclear proteins (Figure 5B). PAK-200S at 2.0 mM had no effect on
the topotecan-mediated inhibition of TOP-I unwinding activity of
pBR322 plasmid DNA (Figure 5C), results which indicate that








































Figure 2 Effect of the dihydropyridine analogue PAK-200S on the time-
dependent cellular topotecan lactone concentrations in parental MCF-7/wt
(rectangles) and resistant MCF-7/adr (circles) cells. Drug exposure and
RP-HPLC analysis were performed as described in Materials and Methods.
Cells were exposed to 1.0 mM TPT without (open symbols) or in the presence
of 2.0 mM PAK-200S (closed symbols), respectively. (P < 0.01 for steady-
state levels at approximately 20 min for MCF-7/adr cells with and without
PAK-200S)
A TOP-I TOP-II




























































Figure 3 Western blot analysis of TOP-I and -II protein expression in
MCF-7/wt and MCF-7/adr cells (A). Fifty micrograms of nuclear proteins were
dissolved on a 7.5% SDS-polyacrylamide gel and electroblotted to
nitrocellulose. Binding of a specific human mAb against TOP-I was visualized
with the enhanced chemiluminescence detection using a protein
A–horseradish peroxidase complex, binding of a polyclonal rabbit Ab with
TOP-II was visualized using a mouse anti-rabbit mAb, respectively. In
addition, the effect of PAK-200S on TOP-I and -II protein expression in
MCF-7/adr cells was determined (B). MCF-7/adr cells were exposed to
2.0 mM PAK-200S for 24 h prior to extraction of nuclear proteins1308 U Vanhoefer et al
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DISCUSSION
The present study demonstrates that: (a) expression of the
membrane transporter P-gp may result in decreased cellular drug
concentrations of the pharmacologically active closed-ring lactone
of topotecan, (b) dihydropyridine analogue PAK-200S, a new
potent MDR-reversing agent, almost completely reverses resis-
tance to topotecan in P-gp-expressing MCF-7/adr and A2780/Dx5
cells, with no effect on parental cells, and (c) reversal of topotecan
resistance by PAK-200S is related to restoration of drug concentra-
tions of the closed-ring lactone of topotecan rather than a direct
effect on topoisomerases. Non-cytotoxic concentrations of PAK-
200S (2.0 mM) completely restored cellular concentrations of the
active lactone form of topotecan in MCF-7/adr cells (Figure 2),
with no effect on parental cells lacking P-gp expression.
Furthermore, restoration of cellular lactone concentrations by
PAK-200S resulted in higher steady-state levels of PLDBs, the
critical cytotoxic lesions of TOP-I interactive agents (Holm et al,
1989; Hsiang et al, 1989).
PAK-200S had no effect on the cellular TOP-I protein expres-
sion and enzyme activity (Figures 3B and 5) and no alterations of
TOP-II expression were observed. These results are of importance
because DNA topoisomerases I and II perform related functions,
and TOP-II has been shown to compensate for TOP-I function
(Uemura et al, 1984; Yang et al, 1987; Eng et al, 1990; Sugimoto et
al, 1990; Friedman et al, 1994). The level of nuclear TOP-II is
linked to cell proliferation, increasing during S phase and dropping
to low levels during G1 phase (Markovits et al, 1987). TOP-II
expression was slightly decreased in resistant MCF-7/adr cells
(Figure 3A), however, no differences in cell doubling time were
found between MCF-7/wt and MCF-7/adr cells (U Vanhoefer
et al, unpublished data).
The reversible cellular hydrolysis of the pharmacologically
active closed-ring lactone to the inactive open-ring hydroxy acid
of topotecan has been shown to be pH-dependent (Grochow et al,
1992). PAK-200S at a concentration of 2.0 mM showed no effect on
the pH of whole cell lysates of MCF-7/adr cells. In addition, no
differences were found between MCF-7/wt and resistant MCF-
7/adr cells in terms of cellular pH (data not shown). Based on these
data, reversal of topotecan resistance by PAK-200S is likely
related to inhibition of P-gp function in MCF-7/adr cells.
Previous studies on drug-selected P-gp-expressing MDR cells
(Hendricks et al, 1992; Mattern et al, 1993; Maliepaard et al, 1996)
and MDR1 cDNA-transfected NIH 3T3 cells (Hoki et al, 1997)
showed that expression of P-gp may confer resistance to positively
charged TOP-I interactive agents (e.g. topotecan). Furthermore,
inhibition of P-gp function by quinidine resulted in an increased
accumulation of topotecan in MCF-7/adriar and KG1a cells
(Hendricks et al, 1992). Of importance is that irinotecan (CPT-11;
[7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-CPT])

































































Figure 4 Effect of PAK-200S on TPT-induced protein-linked DNA breaks
(PLDBs) in resistant MCF-7/adr cells. Cells were exposed to different
concentrations of TPT with or without 2.0 mM PAK-200S. Quantitation of
PLDBs was performed by the KCl–SDS co-precipitation assay as described
in Materials and Methods; results were calculated as percentage of







Figure 5 Topotecan-mediated inhibition of TOP-I unwinding activity of
pBR322-plasmid DNA ex vivo in the absence or presence of PAK-200S.
Twenty to 640 ng of nuclear extract proteins of MCF-7/adr cells were
incubated with a pBR322-plasmid DNA reaction mixture. pBR322 plasmid
DNA with purified TOP-I enzyme [3 U] (lane 1); pBR322 plasmid DNA (lane
2); pBR322 plasmid DNA with 20 ng, 40 ng, 80 ng, 160 ng, 320 ng and
640 ng nuclear extract proteins (lanes 3–8). No drugs (A), 100 mM TPT (B),
or 100 mM TPT and 2.0 mM PAK-200S (C), respectivelythecin) appear not to be substrates for P-gp-mediated drug resis-
tance in vitro and in vivo (Jansen et al, 1998). In addition,
P-gp- and MRP-independent mechanisms of membrane protein-
associated resistance to topotecan have been observed (Yang et al,
1995; Ma et al, 1998). Yang and co-workers (1995) reported in a
mitoxantrone-resistant cell line an energy-dependent efflux of
topotecan associated with a high level of drug resistance and
reduced steady-state levels of topotecan-mediated TOP-I
enzyme/DNA complexes. In the present study, PAK-200S restored
cellular concentrations of topotecan in MCF-7/adr cells, which
was associated with an increased induction of protein-linked DNA
breaks. However, additional TOP-I specific effects of PAK-200S
as mechanisms of chemosensitization to topotecan in MCF-7/adr
cells cannot be excluded and need further investigation.
The dihydropyridine analogue PAK-200S almost completely
restored drug response to topotecan in human MCF-7/adr breast
and A2780/Dx5 ovarian MDR cells, whereas resistance to doxo-
rubicin was only partially reversed, results that are likely related to
the fact that P-gp-mediated resistance to topotecan appears to be
evident to a considerably lesser extent than that observed for other
P-gp substrates (e.g. taxanes, anthracyclines). PAK-104P, a struc-
turally related pyridine analogue, reversed in vitro and in vivo
MRP-mediated multidrug resistance associated with an inhibition
of the ATP-dependent [3H]leukotriene C4 transport in membrane
vesicles of MRP-expressing CA120 cells (Vanhoefer et al, 1996;
Chuman et al, 1997). In addition, data from our laboratory showed
that PAK-200S at non-cytotoxic concentrations significantly
reversed MRP-mediated 250-fold resistance to doxorubicin in
MRP-expressing human fibrosarcoma HT1080/Dr4 cells. Since
recent data suggest that MRP may also confer resistance to
topotecan in vitro (Jonsson et al, 1997; Jansen et al, 1998) and
in vivo (U Vanhoefer et al, unpublished data), PAK-200S may
have clinical advantages over other MDR-reversing agents
(e.g. PSC-833), lacking significant inhibition of MRP-function
(Twentyman et al, 1994; Vanhoefer et al, 1996).
Based on the data reported herein, the dihydropyridine analogue
PAK-200S is a potent reversing agent of membrane protein-
associated resistance to topotecan and therefore merits further
preclinical and clinical investigation.
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